Patents by Inventor THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140127214Abstract: The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases or disorders.Type: ApplicationFiled: April 9, 2013Publication date: May 8, 2014Applicants: Immune Disease Institute, Inc., The Brigham and Women's Hospital, Inc., President and Fellows of Harvard CollegeInventors: Immune Disease Institute, Inc., President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
-
Publication number: 20130336934Abstract: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided.Type: ApplicationFiled: March 13, 2013Publication date: December 19, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
-
Publication number: 20130317030Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: ApplicationFiled: March 7, 2013Publication date: November 28, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
-
Publication number: 20130296198Abstract: The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from cell or tissue samples, such as cancer cell or tissue samples. The invention also provides sets of genes that are expressed differentially in normal and cancer lung cells and tissues. These sets of genes can be used to discriminate between normal and malignant cells or tissues, and between classes of malignant cells or tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided.Type: ApplicationFiled: May 24, 2013Publication date: November 7, 2013Inventor: The Brigham and Women's Hospital, Inc.
-
Publication number: 20130195895Abstract: The invention relates to methods of modulating immune responses in a subject such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.Type: ApplicationFiled: January 25, 2013Publication date: August 1, 2013Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
-
Publication number: 20130195809Abstract: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: The Brigham And Women's Hospital, Inc.
-
Publication number: 20130195810Abstract: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
-
Publication number: 20130183688Abstract: The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.Type: ApplicationFiled: November 6, 2012Publication date: July 18, 2013Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
-
Publication number: 20130177549Abstract: This invention relates generally to treating synucleinopathies in subjects that are not clinically diagnosed with a lysosomal storage disease, as well as associated methods of making medicaments and screening methods.Type: ApplicationFiled: March 1, 2013Publication date: July 11, 2013Applicant: The Brigham and Women's Hospital, Inc.Inventor: The Brigham and Women's Hospital, Inc.
-
Publication number: 20130130348Abstract: A method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. The nanoparticle may contain a drug. The moiety may include a polypeptide or a polynucleotide, such as an aptamer. The moiety may be a targeting moiety, an imaging moiety, a chelating moiety, a charged moiety, or a therapeutic moiety. Another aspect is directed to systems and methods of producing such polymeric conjugates. In some embodiments, a solution containing a polymer is contacted with a liquid, such as an immiscible liquid, to form nanoparticles containing the polymeric conjugate. Other methods use such libraries, use or administer such polymeric conjugates, or promote the use of such polymeric conjugates. Kits involving such polymeric conjugates are also described.Type: ApplicationFiled: November 9, 2012Publication date: May 23, 2013Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
-
Publication number: 20130092158Abstract: The present invention is directed to devices, systems, and methods for monitoring inhaled drug usage to predict when an acute attack or exacerbation of a disease, such as a respiratory disease, is imminent. Instrumented inhalers that use modular designs with standard components are disclosed, as are systems for monitoring the instrumented inhalers. Also disclosed are methods for determining whether or not a patient's inhaled drug usage pattern indicates that an acute attack or disease exacerbation is imminent, and notifying appropriate medical personnel of any usage patterns indicative of an attack or disease exacerbation. If such an attack or exacerbation is imminent, additional therapeutic agents may be dispensed to the patient or other interventions made.Type: ApplicationFiled: November 28, 2012Publication date: April 18, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.